

# Oncolytic Viral Therapy Market - 2024-2033

<https://marketpublishers.com/r/OEC6546D3ABBEN.html>

Date: June 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: OEC6546D3ABBEN

## Abstracts

The Oncolytic Viral Therapy Market was valued at US\$ 24.48 Million in 2024 and is anticipated to reach US\$ 164.51 Million by 2033, at a CAGR of 0.238 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Oncolytic Viral Therapy Market.

This report delivers a comprehensive overview of the Oncolytic Viral Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncolytic Viral Therapy Market. The Oncolytic Viral Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Oncolytic Viral Therapy Market Scope:

Key Players

Amgen, Inc.

Major Highlights

This report delivers a comprehensive overview of the Oncolytic Viral Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncolytic Viral Therapy Market. The Oncolytic Viral Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. MARKET INTRODUCTION AND SCOPE**

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### **2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS**

### **3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS**

- 3.1. Key Trends and Future Projections

### **4. SNIPPET BY VIRUS TYPE**

- 4.1. Snippet by Application
- 4.2. Snippet by Mode of Administration
- 4.3. Snippet by End-User
- 4.4. Snippet by Region

### **5. DYNAMICS**

#### 5.1. Impacting Factors

##### 5.1.1. Drivers

- 5.1.1.1. Rising Prevalence of Cancer and Unmet Treatment Needs

- 5.1.1.2. Personalization & Biomarker-Driven Development

- 5.1.1.3. Rising Advancements in Oncolytic Viral Therapy

##### 5.1.2. Restraints

- 5.1.2.1. High Costs Associated with Oncolytic Viral Therapy

- 5.1.2.2. Safety and Regulatory Stringency

##### 5.1.3. Opportunity

- 5.1.3.1. Expansion into Hard-to-Treat, Immunologically Cold Tumors

- 5.1.3.2. Next-Generation Engineered Viruses as Therapeutic Platforms

##### 5.1.4. Impact Analysis

### **6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK**

#### 6.1. Market Leaders and Pioneers

- 6.1.1. Emerging Pioneers and Prominent Players
- 6.1.2. Established Leaders with the Largest Marketing Brand
- 6.1.3. Market Leaders with Established Products
- 6.2. Latest Developments and Breakthroughs
- 6.3. Regulatory and Reimbursement Landscape
  - 6.3.1. North America
  - 6.3.2. Europe
  - 6.3.3. Asia Pacific
  - 6.3.4. South America
  - 6.3.5. Middle East & Africa
- 6.4. Porter's Five Forces Analysis
- 6.5. Supply Chain Analysis
- 6.6. Patent Analysis
- 6.7. SWOT Analysis
- 6.8. Unmet Needs and Gaps
- 6.9. Recommended Strategies for Market Entry and Expansion
- 6.10. Pricing Analysis and Price Dynamics

## **7. ONCOLYTIC VIRAL THERAPY MARKET, BY VIRUS TYPE**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
  - 7.1.2. Market Attractiveness Index, By Virus Type
- 7.2. Adenoviruses\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Herpes Simplex Virus
- 7.4. Maraba Virus
- 7.5. Measles
- 7.6. Newcastle Disease Virus
- 7.7. Picornavirus
- 7.8. Reovirus
- 7.9. Vaccinia Virus
- 7.10. Vesicular Stomatitis Virus
- 7.11. Others

## **8. ONCOLYTIC VIRAL THERAPY MARKET, BY APPLICATION**

- 8.1. Introduction

- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Melanoma\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Breast Cancer
- 8.4. Prostate Cancer
- 8.5. Ovarian Cancer
- 8.6. Lung Cancer
- 8.7. Pancreatic Cancer
- 8.8. Colorectal Cancer
- 8.9. Head and Neck Cancer
- 8.10. Others

## **9. ONCOLYTIC VIRAL THERAPY MARKET, BY MODE OF ADMINISTRATION**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration
  - 9.1.2. Market Attractiveness Index, By Mode of Administration
- 9.2. Intratumoral Injection\*
  - 9.2.1. Introduction
  - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Intravenous Infusion
- 9.4. Intracavitary Injection
- 9.5. Others

## **10. ONCOLYTIC VIRAL THERAPY MARKET, BY END-USER**

- 10.1. Introduction
  - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals\*
  - 10.2.1. Introduction
  - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Oncology Centers
- 10.4. Ambulatory Surgical Centers
- 10.5. Cancer Research Institutes
- 10.6. Others

## **11. ONCOLYTIC VIRAL THERAPY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES**

### **12. INTRODUCTION**

#### 12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

##### 12.1.1. Market Attractiveness Index, By Region

#### 12.2. North America

##### 12.2.1. Introduction

##### 12.2.2. Key Region-Specific Dynamics

##### 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type

##### 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

##### 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration

##### 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

##### 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

###### 12.2.7.1. U.S.

###### 12.2.7.2. Canada

###### 12.2.7.3. Mexico

#### 12.3. Europe

##### 12.3.1. Introduction

##### 12.3.2. Key Region-Specific Dynamics

##### 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type

##### 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

##### 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration

##### 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

##### 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

###### 12.3.7.1. Germany

###### 12.3.7.2. UK

###### 12.3.7.3. France

###### 12.3.7.4. Spain

###### 12.3.7.5. Italy

###### 12.3.7.6. Rest of Europe

#### 12.4. Asia-Pacific

##### 12.4.1. Introduction

##### 12.4.2. Key Region-Specific Dynamics

##### 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type

##### 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration

12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.4.7.1. China

12.4.7.2. India

12.4.7.3. Japan

12.4.7.4. South Korea

12.4.7.5. Rest of Asia-Pacific

12.5. South America

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type

12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration

12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.5.7.1. Brazil

12.5.7.2. Argentina

12.5.7.3. Rest of South America

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type

12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Administration

12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

## **13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

## **14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS**

14.1. Market Share Analysis and Positioning Matrix

14.2. Strategic Partnerships, Mergers & Acquisitions

14.3. Key Developments in Product Portfolios and Innovations

14.4. Company Benchmarking

## **15. COMPANY PROFILES**

### 15.1. Amgen, Inc.\*

#### 15.1.1. Company Overview

#### 15.1.2. Product Portfolio

##### 15.1.2.1. Product Description

##### 15.1.2.2. Product Key Performance Indicators (KPIs)

## **16. FINANCIAL OVERVIEW**

### 16.1. Company Revenue

#### 16.1.1. Geographical Revenue Shares

##### 16.1.1.1. Revenue Forecasts

#### 16.1.2. Key Developments

##### 16.1.2.1. Mergers & Acquisitions

##### 16.1.2.2. Key Product Development Activities

##### 16.1.2.3. Regulatory Approvals, etc.

#### 16.1.3. SWOT Analysis

### 16.2. Daiichi Sankyo Co., Ltd.

### 16.3. Lokon Pharma AB

### 16.4. Virogin Biotech Canada Ltd

### 16.5. KaliVir Immunotherapeutics, Inc.

### 16.6. Transgene SA

### 16.7. Vyriad, Inc.

### 16.8. Coastar Theapeutics Inc.

### 16.9. IconOVir Bio, Inc.

### 16.10. Calidi Biotherapeutics, Inc. (LIST NOT EXHAUSTIVE\*)

## **17. ASSUMPTIONS AND RESEARCH METHODOLOGY**

### 17.1. Data Collection Methods

### 17.2. Data Triangulation

### 17.3. Forecasting Techniques

### 17.4. Data Verification and Validation

## **18. APPENDIX**

### 18.1. About Us and Services

### 18.2. Contact Us

## I would like to order

Product name: Oncolytic Viral Therapy Market - 2024-2033

Product link: <https://marketpublishers.com/r/OEC6546D3ABBEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OEC6546D3ABBEN.html>